Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 18/20 | 0.80 |
| ▸ | KDR | P35968 | 17/20 | 0.80 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.64 |
| ▸ | KIT | P10721 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7490931 | 0.89 | PDGFRA (1.00) | PDGFRAKDRKIT | |
| SCHEMBL718279 | 0.86 | DDR2 (0.67) | PDGFRAKDRDDR2KIT | |
| SCHEMBL12503730 | 0.86 | PDGFRA (0.86) | PDGFRAKDRKIT | |
| SCHEMBL8070553 | 0.85 | PDGFRA (0.94) | PDGFRAKDRKIT | |
| SCHEMBL10073791 | 0.85 | PDGFRA (0.84) | PDGFRAKDRKIT | |
| SCHEMBL7479600 | 0.85 | PDGFRA (1.00) | PDGFRAKDR | |
| SCHEMBL1878386 | 0.84 | PDGFRA (0.92) | PDGFRAKDRKIT | |
| SCHEMBL3931065 | 0.84 | PDGFRA (1.00) | PDGFRAKDR | |
| SCHEMBL29973354 | 0.83 | PDGFRA (0.95) | PDGFRAKDR | |
| SCHEMBL27081475 | 0.83 | PDGFRA (0.95) | PDGFRAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957087-B2 | Heterocyclic substituted acardite derivate and application thereof | Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) | 2015-02-17 | — | — | US | disclosed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | PDGFRA 1115/4885KDR 3633/4885DDR2 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.